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Abstract: Importance: Conventional adjuvant radiotherapy for breast cancer given daily for several
weeks is onerous and expensive. Some patients may be obliged to choose a mastectomy instead, and
some may forgo radiotherapy altogether. We proposed a clinical trial to test whether radiotherapy could
be safely limited to the tumor bed. Objective: To determine whether delayed second-procedure targeted
intraoperative radiotherapy (TARGIT-IORT) is noninferior to whole-breast external beam radiotherapy
(EBRT) in terms of local control. Design, setting, and participants: In this prospective, randomized (1:1
ratio) noninferiority trial, 1153 patients aged 45 years or older with invasive ductal breast carcinoma
smaller than 3.5 cm treated with breast conservation were enrolled from 28 centers in 9 countries. Data
were locked in on July 3, 2019. Interventions: The TARGIT-A trial was started in March 2000; patients
were randomized after needle biopsy to receive TARGIT-IORT immediately after lumpectomy under the
same anesthetic vs EBRT and results have been shown to be noninferior. A parallel study, described in
this article, was initiated in 2004; patients who had their cancer excised were randomly allocated using
separate randomization tables to receive EBRT or delayed TARGIT-IORT given as a second procedure
by reopening the lumpectomy wound. Main outcomes and measures: A noninferiority margin for local
recurrence rate of 2.5% at 5 years, and long-term survival outcomes. Results: Overall, 581 women (mean
[SD] age, 63 [7] years) were randomized to delayed TARGIT-IORT and 572 patients (mean [SD] age, 63
[8] years) were randomized to EBRT. Sixty patients (5%) had tumors larger than 2 cm, or had positive
nodes and only 32 (2.7%) were younger than 50 years. Delayed TARGIT-IORT was not noninferior to
EBRT. The local recurrence rates at 5-year complete follow-up were: delayed TARGIT-IORT vs EBRT
(23/581 [3.96%] vs 6/572 [1.05%], respectively; difference, 2.91%; upper 90% CI, 4.4%). With long-term
follow-up (median [IQR], 9.0 [7.5-10.5] years), there was no statistically significant difference in local
recurrence-free survival (HR, 0.75; 95% CI, 0.57-1.003; P = .052), mastectomy-free survival (HR, 0.88;
95% CI, 0.65-1.18; P = .38), distant disease-free survival (HR, 1.00; 95% CI, 0.72-1.39; P = .98), or
overall survival (HR, 0.96; 95% CI, 0.68-1.35; P = .80). Conclusions and relevance: These long-term data
show that despite an increase in the number of local recurrences with delayed TARGIT-IORT, there was
no statistically significant decrease in mastectomy-free survival, distant disease-free survival, or overall
survival. Trial registration: ISRCTN34086741, ClinicalTrials.gov Identifier: NCT00983684.
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IMPORTANCE Conventional adjuvant radiotherapy for breast cancer given daily for several
weeks is onerous and expensive. Some patients may be obliged to choose amastectomy
instead, and somemay forgo radiotherapy altogether. We proposed a clinical trial to test
whether radiotherapy could be safely limited to the tumor bed.
OBJECTIVE To determine whether delayed second-procedure targeted intraoperative
radiotherapy (TARGIT-IORT) is noninferior to whole-breast external beam radiotherapy
(EBRT) in terms of local control.
DESIGN, SETTING, AND PARTICIPANTS In this prospective, randomized (1:1 ratio) noninferiority
trial, 1153 patients aged 45 years or older with invasive ductal breast carcinoma smaller than
3.5 cm treated with breast conservation were enrolled from 28 centers in 9 countries. Data
were locked in on July 3, 2019.
INTERVENTIONS The TARGIT-A trial was started in March 2000; patients were randomized
after needle biopsy to receive TARGIT-IORT immediately after lumpectomy under the same
anesthetic vs EBRT and results have been shown to be noninferior. A parallel study, described
in this article, was initiated in 2004; patients who had their cancer excised were randomly
allocated using separate randomization tables to receive EBRT or delayed TARGIT-IORT given
as a second procedure by reopening the lumpectomywound.
MAIN OUTCOMES ANDMEASURES A noninferiority margin for local recurrence rate of 2.5% at 5
years, and long-term survival outcomes.
RESULTS Overall, 581 women (mean [SD] age, 63 [7] years) were randomized to delayed
TARGIT-IORT and 572 patients (mean [SD] age, 63 [8] years) were randomized to EBRT. Sixty
patients (5%) had tumors larger than 2 cm, or had positive nodes and only 32 (2.7%) were
younger than 50 years. Delayed TARGIT-IORT was not noninferior to EBRT. The local
recurrence rates at 5-year complete follow-up were: delayed TARGIT-IORT vs EBRT (23/581
[3.96%] vs 6/572 [1.05%], respectively; difference, 2.91%; upper 90%CI, 4.4%). With
long-term follow-up (median [IQR], 9.0 [7.5-10.5] years), there was no statistically significant
difference in local recurrence-free survival (HR, 0.75; 95% CI, 0.57-1.003; P = .052),
mastectomy-free survival (HR, 0.88; 95% CI, 0.65-1.18; P = .38), distant disease-free survival
(HR, 1.00; 95% CI, 0.72-1.39; P = .98), or overall survival (HR, 0.96; 95% CI, 0.68-1.35;
P = .80).
CONCLUSIONS AND RELEVANCE These long-term data show that despite an increase in the
number of local recurrences with delayed TARGIT-IORT, there was no statistically significant
decrease in mastectomy-free survival, distant disease-free survival, or overall survival.
TRIAL REGISTRATION ISRCTN34086741, ClinicalTrials.gov Identifier: NCT00983684
JAMA Oncol. 2020;6(7):e200249. doi:10.1001/jamaoncol.2020.0249
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I
n 2018, therewere 2million new cases of breast cancer di-
agnosedworldwideand626000deaths.1Mostpatients are
suitable for treatmentwith breast-conserving surgery and
adjuvant radiotherapy, rather than total mastectomy. The
TARGIT-A randomized clinical trial (accrual from2000-2012)
compared risk-adapted TARGeted intraoperative radio-
therapy (TARGIT-IORT) during the initial surgical excision of
the cancer2-5 with conventional whole-breast external beam
radiotherapy (EBRT) over several weeks.2,6,7 The results of
this trial demonstrated noninferiority particularly when
TARGIT-IORT was delivered at the time of initial excision of
cancer.
In 2004, 4 years after accrual began in the main
TARGIT-A trial, and at the request of potentially high-volume
centers,wesoughtandreceivedadditional ethics approval and
opened a parallel study. This was previously referred to as
“postpathology stratum” and recruited 1153 patients using a
separate randomization table. Patients were randomized af-
ter their initial surgery to have either conventional fraction-
atedwhole-breast radiotherapy (n = 572), or to undergo a fur-
ther operation to deliver delayed radiotherapy to the wound
(n = 581) by reopening the original incision. This trial was ini-
tiated mainly because of the convenience of easier schedul-
ing of delayed TARGIT-IORT in the operation theater. A po-
tential benefit was that the inclusion criteria could be made
more selective, choosing the patients with better prognosis
based on the full histopathologic results that would be avail-
able after tumor excision. For example, the knowledge of the
Figure 1. Flowchart and CONSORTDiagram
1153 Patients enrolled and randomized after excision of tumor
581 Randomized to delayed 
TARGIT-IORT delivered as a single dose to the
tumor bed with intrabeam to the reopened tumor
bed as a second procedure
572 Randomized to conventional radiotherapy
Standard fractionated EBRT over 3-6 weeks
Eligibility:
Age ≥45 years
Primary tumor already excised
Unifocal invasive ductal carcinoma preferably ≤3.5 cm, cN0-N1
(MRI not required)
Suitable for breast-conserving surgery
Flowchart outlining recruitment to trial of delayed TARGIT-IORT vs EBRTA
CONSORT diagramB
1153 Randomized
581 Randomized to delayed second-procedure TARGIT-IORT
2 Withdrawn from further follow-up
581 Included in analysis
12 Did not receive allocated treatment
2 Received EBRTb
0 Did not receive TARGIT-IORT or EBRT
10 Had a mastectomy
569 Received allocated treatment
538 Received delayed TARGIT-IORT
31 Received TARGIT-IORT plus EBRTc
572 Randomized to EBRT
6 Withdrawn from further follow-upa
572 Included in analysis
18 Did not receive allocated treatment
8 Received TARGIT-IORT and EBRTb
3 Did not receive TARGIT-IORT or EBRT
7 Had a mastectomy
554 Received allocated treatment
554 Received EBRT
EBRT indicates whole-breast external
beam radiotherapy; MRI, magnetic
resonance imaging; TARGIT-IORT,
targeted intraoperative radiotherapy.
A, Flowchart outlining recruitment to
trial of delayed TARGIT-IORT vs EBRT.
B, CONSORT diagram of participant
randomization.
a The difference in number
withdrawnwas not statistically
significant (P = .15).
bAs per protocol, 31 of 581 patients
(5.3%) allocated to delayed
TARGIT-IORT received EBRT after
TARGIT-IORT.
c Two of 581 patients (0.3%)
allocated to delayed TARGIT-IORT




Question For early breast cancer, is 5-year local control with
delayed second-procedure targeted intraoperative radiotherapy
(TARGIT-IORT) noninferior to whole-breast postoperative external
beam radiotherapy (EBRT), and how do long-term outcomes
compare?
Findings In this randomized clinical trial including 1153
participants, delayed second-procedure TARGIT-IORT was not
noninferior to EBRT at 5-year complete follow-up; however,
long-term (median 9 years) mastectomy-free survival, distant
disease-free survival, and overall survival were not different.
Meaning For early breast cancer, delayed second-procedure
single-dose TARGIT-IORT given by reopening the lumpectomy
wound had similar long-termmastectomy-free and overall survival
compared with EBRT despite higher local recurrence.
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microscopically measured tumor size, grade, and nodal sta-
tus could be used to select amuch lower-risk patient popula-
tion before randomization.
This delayed procedurewas performed at amedian (IQR)
of 37 (29-51) days after the initial excision as a second surgical
procedure in the operation theater, rather than immediate in-
traoperative radiotherapy given during the initial cancer op-
eration. This article describes the long-term outcomes of this
parallel study.
Methods
The TARGIT-A trial was a pragmatic, prospective, interna-
tional, multicenter, open label, randomized, phase 3 trial that
compared the policy of risk-adapted TARGIT-IORT vs the con-
ventionalpolicyofwhole-breastEBRT.Thetrialprotocol (https://
njl-admin.nihr.ac.uk/document/download/2006598) and the
details of sample size calculations, the process of random
allocation,havebeenpreviouslydescribed.6,7Thetrialprotocol
is available inSupplement 1.Thestudyreceivedethicsapproval
fromthe jointUniversityCollegeLondonandUniversityCollege
LondonHospital committees of ethics of human research.
Participants
Women were eligible to participate in the delayed TARGIT-
IORT trial if their breast cancer was already excised. They
needed to be aged 45 years or older with unifocal breast can-
cer on examination and conventional imaging. Pragmati-
cally, we permitted individual centers to prespecify the final
postoperative histopathologic criteria that would make pa-
tients eligible for randomization and these were prespecified
in the center’s treatmentpolicydocument. Becausemost cen-
ters specifiedcriteria foreligibility:aged50yearsorolder,grade
1 or 2 disease, and uninvolved nodes, only 5% of patients in
the trial had any adverse prognostic criteria. All patients gave
informedwritten consent andneeded tobe available for regu-
lar follow-up for at least 10 years. Follow-up clinical examina-
tion was at least every 6 months for the first 5 years and an-
nually thereafter, including a mammogram once per year.










Received 26 (4.5) 14 (2.5)
.07Did not receive 553 (95.5) 546 (97.5)
Unknown 2 (0.3) 12 (2.1)
Abbreviations: DCIS, ductal carcinoma in situ; EBRT, whole-breast external
beam radiotherapy; ER, estrogen receptor; PgR, progesterone receptor;
TARGIT-IORT, targeted intraoperative radiotherapy.
a For percentage calculation, the denominator for unknown percentages is the
total number randomized (581 and 572) and the denominator for each
category is the total number of known cases.
bP values are given for differences between TARGIT-IORT and EBRT, calculated
using a χ2 test for known values.










≤50 30 (5.2) 23 (4.02)
.54
51-60 166 (28.6) 171 (29.9)
61-70 302 (52.0) 284 (49.7)
>70 83 (14.3) 94 (16.4)
Pathologic tumor size, mm
≤10 294 (51.0) 290 (51.8)
.79
11-20 249 (43.2) 243 (43.4)
>20 33 (5.7) 27 (4.8)
Unknown 5 (0.9) 12 (2.1)
Grade
1 305 (56.5) 339 (63.8)
.06
2 204 (37.8) 159 (29.9)
3 31 (5.7) 33 (6.2)
Unknown 41 (7.1) 41 (7.2)
Margin
Free 539 (92.9) 520 (92.4)
.46
DCIS only 16 (2.8) 18 (3.2)
Invasive 25 (4.3) 25 (4.5)
Unknown 1 (0.2) 9 (1.6)
Lymphovascular invasion
Absent 536 (94.7) 533 (96.6)
.13Present 30 (5.3) 19 (3.4)
Unknown 15 (2.6) 20 (3.5)
Lymph nodes involved
0 543 (93.6) 537 (95.2)
.39
1-3 34 (5.9) 26 (4.6)
>3 3 (0.5) 1 (0.2)
Unknown 1 (0.2) 8 (1.4)
ER status
Positive 569 (98.3) 550 (97.9)
.62Negative 10 (1.7) 12 (2.1)
Unknown 2 (0.3) 10 (1.7)
PgR status
Positive 440 (81.8) 423 (82.0)
.94Negative 98 (18.2) 93 (18.0)
Unknown 43 (7.4) 56 (9.8)
ERBB2 status
Positive 30 (5.4) 33 (6.0)
.65Negative 526 (94.6) 515 (94.0)
Unknown 25 (4.3) 24 (4.2)
Method of presentation
Screen detected 420 (73.6) 395 (70.5)
.26Symptomatic 151 (26.4) 165 (29.5)
Unknown 10 (1.7) 12 (2.1)
Endocrine therapy
Received 336 (58.0) 334 (59.4)
.63Did not receive 243 (42.0) 228 (40.6)
Unknown 2 (0.3) 10 (1.8)
(continued)
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Random allocation was in a 1:1 ratio, to receive either single-
dose delayed TARGIT-IORT or EBRT as per standard sched-
ules over severalweeks,with randomization blocks stratified
by center. The flowdiagram andCONSORTdiagram are given
in Figure 1A and B.
TheconceptandthedelayedTARGIT-IORTtechniquehave
beendescribedpreviously3-5,8-11 andenabled thesepatients to
have their radiotherapy in 1 sitting, albeit byundergoing a sec-
ond procedure, usually under a general anesthetic.12 Radia-
tion was given over 20 to 50 minutes delivering 20 Gy to the
surfaceof the tumorbedattenuating to5 to7Gyat 1-cmdepth.
The patients in the conventional arm underwent stan-
dard EBRT,which always included fractionatedwhole-breast
radiotherapy for 3 to 6 weeks, with or without an EBRT tu-
mor bedboost, as determinedby local criteria prespecified by
the collaborating center.
Statistical Analysis
The statistical analysis plan (Supplement 1) was signed off on
by the chair of the independent steering committee andan in-
dependent senior statistician before the unblinded datawere
sent to the trial statistician for the current analysis. It speci-
fied theprimaryoutcomeas local recurrence-freesurvival.This
outcome, consistentwith theDATECAN13 andSTEEP14 guide-
lines, estimates the chance of a patient being alivewithout lo-
cal recurrenceandtherefore included local recurrenceordeath
as events, ie, patients who had died were not censored. The
otheroutcomes includedmastectomy-freesurvival,distantdis-
ease-free survival, overall survival, breast cancermortalityand
non–breast cancer mortality. Statistical analysis was per-
formedusingestablishedmethods,usingSTATAstatistical soft-
ware (versions 15.0 and 16.0, STATA Corp) for data compila-
tion, validation, and analysis.13-15 Data analysis took place
between September 11, 2019 to January 15, 2020.
In the original protocol, noninferiority was specified as
being achieved if thedifference in 5-year local recurrence rate
didnot cross a stringentmarginof 2.5%.However,wehaveap-
plied an evenmore rigorous criterion since 2013: that the up-
per 90%CI of the absolute difference in the binomial propor-
tions of local recurrence rate at 5-year complete follow up
should not cross 2.5% in absolute terms.
Kaplan-Meier graphswere displayed as recommendedby
Pocock et al,16who recommend that thex-axis of these graphs
should be extended until 10% to 20%of patients are at risk of
an event. The log-rank test was used to compare the differ-
ence between survival functions and to obtain P values.
Main Outcomes andMeasures
Thecauseofdeathwas specifiedby thecenter. If thecausewas
specified as a non–breast cancer event and no distant disease
was recorded, it was defined as a non–breast cancer death. If
the death was recorded by the center to be related to breast
cancer, or as per convention, if breast cancer was present at
the time of death, or if the cause of deathwas recorded as un-
known or uncertain, it was presumed to be a breast cancer
death.
Figure 1B shows the CONSORT diagram, which describes
the treatment received in each of the randomized arms. The
reference date for completeness was May 2, 2018, 8 years af-
ter the first data lock.Apatientwas consideredashaving com-
plete follow-up if theywere seen for the specified duration of
follow-up, had died, or had withdrawn from the trial. As the
lastpatientwasrandomized in2012, thestatisticalanalysisplan
specified that the 5-year follow-upwould be considered com-
plete if 95% of patients had complete follow-up. It also speci-
fied that 10-year follow-up would be considered complete if
the patient had at least 10 years of follow-up, had been seen
within 1 year of the reference date, or had died orwithdrawn;
the 10-year follow-upwouldbeconsideredcomplete if thiswas
achievedby90%ofpatients.Because therewasnospecific trial
funding for individual centers, return of follow-up relied on
individual investigators and their teams’ efforts, enthused by
the trial-center team.The trial statistician and the chief inves-
tigator produced reports of completeness of follow up using
blindeddatabases on a regular basis. As recommendedby the
independent steering committee, the database was un-
blinded for analysis once theprespecified goals for complete-
ness of followupwere achieved. The referencedate for analy-
Figure 2. Actual Follow-up and Expected Follow-up
for the Trial of Delayed Second-Procedure TARGIT-IORT vs EBRT
0





















Delayed TARGIT-IORT (expected) 581 574 567 555 417 208 88
581 570 562 542 402 197 83
572 563 555 543 406 180 74





EBRT indicates whole-breast external
beam radiotherapy; TARGIT-IORT,
targeted intraoperative radiotherapy.
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siswas 3 July 2019, so that all events upuntil 2 July 2019were
included foranalysis.Thechief investigator/correspondingau-
thor and the trial statistician (J.S.V. and Ma.B.) had access to
all data sent by the trial center for analysis; all authors were
responsible for thedecision to submit thearticle. Since the last
analysis, the trial oversight has beenprovided by an indepen-
dent steering committee, appointed by the Health Technol-
ogyAssessmentprogramof theNational InstituteofHealthRe-
search, Department of Health, United Kingdom.
Results
Overall, 581 women were randomized to delayed TARGIT-
IORT and 572 to EBRT. The patient and tumor characteristics
are given in Table 1 and were well matched between the ran-
domization arms. Most patients were estrogen receptor posi-
tive (1119 [98%]), ERBB2 negative (1041 [94%]); 670 patients
(58%) receivedendocrine therapy, and40 (3.5%) receivedche-
Table 2. Twelve-Year Kaplan-Meier Estimates of OutcomesMeasures for TARGIT-IORT vs EBRT
Outcomes





(95% CI) HR (95% CI) P value for log rank
Local recurrence-free survivala
Estimate 0.75 (0.57-1.003) .052
5-y 41 92.87 (90.44-94.70) 19 96.63 (94.77-97.84)
10-y 98 80.16 (76.19-83.54) 72 84.36 (80.51-87.51)
12-y 106 75.30 (70.13-79.72) 79 78.38 (72.32-83.27)
Invasive local recurrence-free survivala
Estimate 0.75 (0.56-1.002) .051
5-y 38 93.39 (91.03-95.15) 17 96.99 (95.20-98.12)
10-y 95 80.68 (76.73-84.02) 68 85.15 (81.35-88.23)
12-y 103 75.87 (70.72-80.24) 75 79.23 (73.23-84.04)
Mastectomy-free survivala
Estimate 0.88 (0.65-1.18) .38
5-y 39 93.24 (90.87-95.02) 23 95.93 (93.93-97.27)
10-y 82 83.79 (80.14-86.83) 75 83.82 (79.94-87.01)
12-y 92 77.80 (72.57-82.16) 79 80.44 (75.16-84.71)
Distant disease-free survivala
Estimate 1.00 (0.72-1.39) .98
5-y 26 95.49 (93.44-96.90) 18 96.80 (94.97-97.97)
10-y 62 87.50 (84.13-90.19) 62 86.91 (83.37 89.74)
12-y 71 81.98 (76.91-86.04) 67 82.18 (76.44-86.65)
Overall survival
Estimate 0.96 (0.68-1.35) .80
5-y 19 96.70 (94.87-97.88) 13 97.69 (96.06-98.65)
10-y 56 88.62 (85.35-91.19) 56 87.77 (84.22-90.56)
12-y 65 83.13 (78.11-87.10) 59 84.72 (79.52-88.70)
Breast cancer mortality
Estimate 0.81 (0.43-1.52) .50
5-y 9 1.58 (0.82-3.01) 4 0.72 (0.27-1.90)
10-y 20 3.79 (2.45-5.83) 16 3.50 (2.11-5.77)
12-y 21 4.39 (2.77-6.93) 17 4.63 (2.52-8.43)
Mortality from other causes
Estimate 1.02 (0.68-1.55) .89
5-y 10 1.75 (0.95-3.23) 9 1.60 (0.84-3.06)
10-y 36 7.90 (5.69-10.90) 40 9.05 (6.62-12.31)
12-y 44 13.05 (9.35-18.05) 42 11.17 (7.78-15.88)
Abbreviations: EBRT, whole-breast external beam radiotherapy; HR, hazard ratio; TARGIT-IORT, targeted intraoperative radiotherapy.
a Each of these survival measures include death as an event.
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motherapy. The completeness of follow-up is demonstrated
in Figure 2.
At 5-year complete follow-up, the local recurrence rates
were TARGIT-IORT, 23 (including 3 DCIS) of 581 (3.96%) vs
EBRT, 6 (including 2 DCIS) of 572 (1.05%), giving a difference
of 2.9%with its upper 90% CI of 4.4, which crossed the non-
inferiority margin of 2.5%.
Kaplan-Meier estimates and log-rank P values for de-
layedTARGIT-IORTvs EBRT are given inTable 2 andFigure 3.
The median follow-up was 9 years and the differences be-
tween delayed TARGIT-IORT and EBRT were not statistically
significant for local recurrence-free survival, invasive local re-
currence-free survival,mastectomy-free survival, distant dis-
ease-free survival, breast cancer mortality, non–breast can-
cermortality,andoverall survival.Nopatientshaduncontrolled
local recurrence at the time of death.
Discussion
The TARGIT-A trial was originally conceived because of the
clinicopathologicobservationthat local recurrenceafterbreast-
conserving surgery occurs predominantly in the index
quadrant,17,18 despite the fact thatmore than 60%of patients
suitable for breast conserving surgery are known to havemi-
croscopic foci of the disease outside the index quadrant.17-19
ThedelayedTARGIT-IORTapproachwasproposedmainly
for logistical reasons. It allowed better planning of operation
theaters as well as theoretically stricter selection of patients
with low-risk disease based on final histopathologic analysis
results. It also allowed using TARGIT-IORT in patients com-
ing to a cancer center after having had their cancer excised in
a smaller or remote hospital. Concordant with the results of
our2013analysis,withmature follow-up (5years complete fol-
low-up with a median of 9 years) delayed TARGIT-IORT was
found not to be noninferior to EBRT in terms of local control,
with theupper 90%confidence limit of the 2.9%absolute dif-
ference in the 5-year local recurrence rate being 4.4%, which
is above our stringent 2.5% noninferiority margin.
This noninferioritymargin of 2.5%wasdecided after con-
siderable thought,6 and is much more stringent than the 7%
margin set in the in the ELIOT trial, the only other trial to our
knowledge of intraoperative radiotherapy.20 We believe that
it is important to consider how much the absolute differ-
Figure 3. Twelve-Year Kaplan-Meier Curves Comparing Delayed Second-Procedure TARGIT-IORT vs EBRT
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ences seen in the trial matter to the patient. When consider-
ing treatments for patients with early breast cancer, local re-
currence has been given great importance because of the
perceived risk of consequent mastectomy, the danger of dis-
tant disease, and the potentially lower survival. The long-
termdata show that therewasno impairment ofmastectomy-
free survival, distant disease-free survival, or overall survival,
up to 12 years from randomization (Figure 3).Moreover, qual-
ityof life studieshave shownthatdespitehavinga secondpro-
cedure, thequalityof life andpatient-reportedoutcomes, such
ascosmesis, breast-relatedqualityof life, andbreastpain,have
beendemonstrated tobe superiorwithTARGIT-IORT,21,22 and
this approach is preferred by patients even in the face of a hy-
pothetically higher local recurrence risk.23,24 These findings
may mitigate some of the patient concerns, and results of
further patient preference research would help these
discussions.
Limitations
The reasons for higher local recurrence with delayed
second-procedure TARGIT-IORT may be multifactorial.
First, the propensity of tumor recurrence in the index quad-
rant could be owing to a tumor promoting effect of the
microenvironment of the surgical wound,25-27 a risk that has
been shown to be beneficially manipulated by TARGIT-IORT
to the fresh tumor bed,25,27,28 but perhaps not when
TARGIT-IORT is given as a delayed second procedure. Sec-
ond, the surgical procedure of lumpectomy has changed.
Early on in the trial, the tissues around the tumor bed were
often not approximated after lumpectomy, and the tumor
bed remained easily identifiable as a fluid-filled cavity at
the time of the second procedure, although some healing
had already occurred and fibrosis was setting in by the time
the delayed TARGIT-IORT was delivered (median, 37 days
later). A limitation of the study was that we did not antici-
pate a change in surgical practice in later years, such that
the tumor bed was approximated after tumor excision
rather than leaving a cavity. The resultant scarring could
have made it difficult to accurately locate the primary
tumor bed. Given the rapid attenuation of dose, with dis-
tance from the applicator surface, adequate dose may not
have reached the original tumor bed. Finally, one can also
speculate that the additional surgical trauma owing to the
necessary second procedure in every case of delayed
TARGIT-IORT could stimulate residual cancer cells. Not-
withstanding these theoretical reasons, the final judgments
must be based on the long-term outcomes data.
Conclusions
Partial breast irradiation was heralded as a new standard29 at
the timeof the first publicationof theTARGIT-A trial6 and sev-
eral other supporting clinical trials have since been pub-
lished: including the ELIOT trial ,20 interstit ial
wire-brachytherapy,30 and partial breast EBRT.31,32 Based on
the randomized evidence of immediate TARGIT-IORT, which
has been shown to be an effective alternative to EBRT,6,7,33 it
is clear that the preferred timing of using TARGIT-IORT is im-
mediately—during the initial surgical excision of breast can-
cer.However,when immediateTARGIT-IORThasnotbeenpos-
sible, the long-term data presented in this article may help
informdiscussionsbycliniciansandpatientswhowishtoavoid
a prolonged postoperative course of EBRT.
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